Cellectis S.A.
CLLSHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeCellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of. The $264.8M market capitalization puts CLLS squarely in micro-cap range for its industry. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Market Cap
$264.8M
Beta
2.77
P/E (TTM)
—
P/E (Fwd)
-4.24
EPS (TTM)
$-0.67
EPS (Fwd)
$-0.62
ROE
-76.3%
ROA
-8.4%
Cash
$185.4M
Total Debt
$82.3M
Free CF
$91.4M
52W Change
44.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $185.4M in cash comfortably exceeding the $82.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $91.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -76.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $19.2M (2022) to $72.9M (2025), reflecting a 281% increase over the period.
With a beta above 1.5, CLLS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CLLS has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CLLS.